Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
暂无分享,去创建一个
Hartwig Huland | Markus Graefen | Andreas Erbersdobler | Hans Lilja | Alexander Haese | A. Haese* | H. Lilja | M. Graefen | T. Steuber | H. Huland | J. Noldus | A. Erbersdobler | Joachim Noldus | Thomas Steuber | Charlotte Becker | Edith Huland | C. Becker | E. Huland
[1] A. Haese*,et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ‐confined from locally‐advanced prostate cancer in total PSA‐levels below 10 ng/ml , 2001, The Prostate.
[2] A. Haese*,et al. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. , 2000, The Journal of urology.
[3] D. Tindall,et al. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. , 1992, Biochemistry.
[4] A. Rademaker,et al. Re: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. , 1990, The Journal of urology.
[5] S. Gautam,et al. Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen. , 2001, The Journal of urology.
[6] D. Tindall,et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. , 1999, Urology.
[7] G G Klee,et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. , 1997, Urology.
[8] T. Stamey,et al. Biological determinants of cancer progression in men with prostate cancer. , 1999, JAMA.
[9] J. Hugosson,et al. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. , 2000, Urology.
[10] B. Morris,et al. Primary structure of a human glandular kallikrein gene. , 1987, DNA.
[11] H. Lilja,et al. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. , 1997, Biochemical and biophysical research communications.
[12] D. Tindall,et al. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. , 1999, Urology.
[13] D. Chan,et al. Standardization of two immunoassays for human glandular kallikrein 2. , 2003, Clinical chemistry.
[14] J. Oesterling,et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.
[15] G. Yousef,et al. The new human tissue kallikrein gene family: structure, function, and association to disease. , 2001, Endocrine reviews.
[16] J. Richie,et al. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. , 1999, The Journal of urology.
[17] A S Whittemore,et al. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer , 1993, Cancer.
[18] T. Stamey,et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. , 1989, The Journal of urology.
[19] H. Lilja,et al. Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections. , 2000, Urology.
[20] T. Stamey,et al. Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients. , 1996, The Journal of urology.
[21] A. Renshaw,et al. Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.